Entera Bio Ltd
ENTX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$471.49M
Close$
$0.14
95.6% downside
Current Fair Value
95.6% downsideOvervalued by 95.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $471.49 Million |
|---|---|
| Enterprise Value | $206.01 Million |
| Earnings per Share | $-0.25 |
| Beta | 1.46 |
| Outstanding Shares | 145,075,070 |
Return
| Return on Equity | 12.67% |
|---|---|
| Return on Assets | 12.54% |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -18.61 |
|---|---|
| PEG | 3.17 |
| Price to Sales | - |
| Price to Book Ratio | 3.25 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | 5 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 6, 2026
EPS Estimate
$-0.07
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
March 26, 2027
EPS Estimate
$-0.15
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.90%▼ 20.37% |
|---|---|
| Total Invested | $1.32M▼ 93.07% |
| Investors Holding | 3▼ 25.00% |
About Entera Bio Ltd
17 employees
CEO: Adam Gridley
Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challeng...